Someone asked me to look at Aiolos Bio’s drug AIO-001, a humanized anti-TSLP monoclonal antibody (developed as a treatment for moderate-to-severe asthma) and guessed that leronlimab may downregulate TSLP.

My reply -

Quote:

---

Thanks for the info. With thousands of proteins out there people leading me to new ones is often why I check them out and see if leronlimab regulates them. I took a look at TSLP and it is upregulated by IL-1b, IL-4, IL-13 and TNF-a. IL-1b, IL-4, IL-13 and TNF-a are all downregulated by leronlimab which in turn would downregulate TSLP. AIO-001 is another drug that does part of what leronlimab does but not all. Which is the case with I think every inflammatory and autoimmune drug I've run across. I've said before that CCR5 is the main controller of the immune system and every time I look it seems to be the case.

AIO-001's ability to downregulate TSLP would control inflammation fairly well so it has a good chance of approval in asthma.

Aiolos Bio just got an infusion of cash to the tune of $245 million dollars if investors knew that leronlimab can do what AIO-001 does and more they would be snapping up shares of Cytodyn. Once we have the results from the immune activation in HIV trial they may get a clue.

---